Favaloro Emmanuel J, Arunachalam Sandya, Dean Elysse
Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia.
Semin Thromb Hemost. 2025 Sep;51(6):629-640. doi: 10.1055/s-0044-1781450. Epub 2024 Mar 1.
D-dimers represent the breakdown products of fibrin. Thus, elevated plasma D-dimers will arise following a thrombotic event, such as a deep vein thrombosis or a pulmonary embolism, and therefore, a nonelevated D-dimer is used to effectively exclude such events. D-dimers are also elevated in a range of other conditions, for example, during disseminated intravascular coagulation. D-dimer levels may also be associated with prognostic value. For example, highly raised D-dimer levels can be associated with worsening clinical features in coronavirus disease 2019. Thus, D-dimer testing represents a commonly requested hemostasis test, often performed in 24/7 laboratories. Unfortunately, D-dimer testing is neither standardized nor harmonized across manufacturers or laboratories. Indeed, considering reporting units and the magnitude of units, up to 28 different combinations may be reported by laboratories. We provide updated findings for D-dimer testing in our geographic region, using recent data from the Royal College of Pathologists of Australasia Quality Assurance Programs, an international external quality assessment program, currently with over 450 participants in the D-dimer module. Data show a wide variety of assays in use and variable outcomes in reported numerical values when assessing proficiency samples. D-dimer testing mostly comprised reagents from three main manufacturing suppliers, with a small number of users of reagents from other manufacturers. Reported results showed important differences in numerical values for the same homogeneous tested samples when normalized to a single reporting unit (e.g., mg/L). Nevertheless, despite using different test reagents and reporting, most participants uniformly identified D-dimer values as below or above a "detection" cut-off for samples that were constructed to be below or above most cut-off values. As expected, mixed findings were reported for samples containing levels around expected cut-off values. We hope that our findings, reflecting on the heterogeneity of test reagents and test data, help improve diagnostic testing for D-dimer testing and facilitate harmonization and standardization, in the future.
D - 二聚体是纤维蛋白的降解产物。因此,在发生血栓形成事件(如深静脉血栓形成或肺栓塞)后,血浆D - 二聚体水平会升高,所以,D - 二聚体水平未升高可有效排除此类事件。在一系列其他情况下,D - 二聚体水平也会升高,例如在弥散性血管内凝血期间。D - 二聚体水平还可能具有预后价值。例如,在2019冠状病毒病中,D - 二聚体水平大幅升高可能与临床症状恶化有关。因此,D - 二聚体检测是一项常用的止血检测项目,通常在全天候运营的实验室中进行。不幸的是,不同制造商或实验室的D - 二聚体检测既未标准化也未统一。实际上,考虑到报告单位和单位大小,实验室可能报告多达28种不同的组合。我们利用来自澳大拉西亚皇家病理学家学院质量保证项目(一个国际外部质量评估项目,目前D - 二聚体模块有超过450名参与者)的最新数据,提供了我们所在地理区域D - 二聚体检测的最新结果。数据显示,在评估能力验证样本时,使用了各种各样的检测方法,报告的数值结果也各不相同。D - 二聚体检测大多采用来自三个主要生产供应商的试剂,只有少数用户使用其他制造商的试剂。当将相同的均质检测样本归一化为单一报告单位(例如mg/L)时,报告结果显示数值存在重要差异。然而,尽管使用了不同的检测试剂和报告方式,但大多数参与者对于构建为低于或高于大多数临界值的样本,都能一致地将D - 二聚体值识别为低于或高于“检测”临界值。正如预期的那样,对于含有接近预期临界值水平的样本,报告结果不一。我们希望我们反映检测试剂和检测数据异质性的研究结果,有助于在未来改进D - 二聚体检测的诊断测试,并促进统一和标准化。